Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Provided By GlobeNewswire
Last update: Aug 19, 2025
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301
Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
NASDAQ:CINGW (12/11/2025, 12:43:35 PM)
0.0553
+0.02 (+49.06%)
NASDAQ:CING (12/11/2025, 1:04:54 PM)
4.02
+0.07 (+1.77%)
Find more stocks in the Stock Screener
